Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2014-06-02 (11 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: BERNIS (30620), Gard
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE DELSOL : revenue, balance sheet and financial ratios
SELARL PHARMACIE DELSOL is a French company
founded 11 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in BERNIS (30620),
this company of category PME
shows in 2018 a revenue of 2.0 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DELSOL (SIREN 802743567)
Indicator
2025
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
1 965 688 €
N/C
Net income
70 265 €
97 207 €
78 389 €
86 736 €
32 442 €
6 809 €
-621 €
EBITDA
N/C
N/C
N/C
N/C
N/C
23 648 €
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
0.3%
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE DELSOL generates positive net income of 70 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
70 265 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 53%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 56%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
52.915%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2025
Debt ratio
433.155
406.332
319.879
254.057
178.375
120.158
52.915
Financial autonomy
15.553
15.921
19.478
24.315
30.898
38.367
56.189
Repayment capacity
None
-81.039
None
None
None
None
None
Cash flow / Revenue
None%
-0.585%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
52.912025
2021
2022
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average-18 pts over 3 years
In 2025, the debt ratio of SELARL PHARMACIE DELSOL (52.91) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
56.19%2025
2021
2022
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good+22 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE DELSOL (56.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE DELSOL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2025
Operating WCR
0 €
100 132 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
0
18
0
0
0
0
0
Customer payment term (days)
0
6
0
0
0
0
0
Supplier payment term (days)
0
46
0
0
0
0
0
Positioning of SELARL PHARMACIE DELSOL in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DELSOL is estimated at
1 116 167 €
(range 757 436€ - 1 751 421€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
757k€1116k€1751k€
1 116 167 €Range: 757 436€ - 1 751 421€
NAF 5 année 2025
Valuation method used
Net Income Multiple
70 265 €
×
15.9x
=1 116 168 €
Range: 757 437€ - 1 751 421€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DELSOL with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DELSOL
What is the revenue of SELARL PHARMACIE DELSOL ?
The revenue of SELARL PHARMACIE DELSOL in 2018 is 2.0 M€.
Is SELARL PHARMACIE DELSOL profitable?
Yes, SELARL PHARMACIE DELSOL generated a net profit of 70 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DELSOL ?
The headquarters of SELARL PHARMACIE DELSOL is located in BERNIS (30620), in the department Gard.
Where to find the tax return of SELARL PHARMACIE DELSOL ?
The tax return of SELARL PHARMACIE DELSOL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DELSOL operate?
SELARL PHARMACIE DELSOL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart